These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1117 related items for PubMed ID: 19637418

  • 1. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
    Smith LS, Nelson M, Dolder CR.
    Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
    [Abstract] [Full Text] [Related]

  • 5. Certolizumab pegol for the treatment of Crohn's disease.
    Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S, PRECISE 1 Study Investigators.
    N Engl J Med; 2007 Jul 19; 357(3):228-38. PubMed ID: 17634458
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease.
    Shao LM, Chen MY, Cai JT.
    Aliment Pharmacol Ther; 2009 Mar 15; 29(6):605-14. PubMed ID: 19183161
    [Abstract] [Full Text] [Related]

  • 11. [Certolizumab pegol--new possibilities in the treatment of Crohn's disease].
    Lazebnik LB, Kniazev OV.
    Eksp Klin Gastroenterol; 2012 Mar 15; (3):100-5. PubMed ID: 22830233
    [No Abstract] [Full Text] [Related]

  • 12. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L.
    Minerva Gastroenterol Dietol; 2010 Jun 15; 56(2):233-43. PubMed ID: 20485259
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.
    Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF.
    Clin Gastroenterol Hepatol; 2008 Jun 15; 6(6):644-53. PubMed ID: 18550004
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.
    Feagan BG, Reilly MC, Gerlier L, Brabant Y, Brown M, Schreiber S.
    Aliment Pharmacol Ther; 2010 Jun 15; 31(12):1276-85. PubMed ID: 20298497
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.
    Tun GS, Lobo AJ.
    Expert Opin Drug Metab Toxicol; 2015 Feb 15; 11(2):317-27. PubMed ID: 25586216
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Certolizumab pegol: in Crohn's disease.
    Blick SK, Curran MP.
    BioDrugs; 2007 Feb 15; 21(3):195-201; discussion 202-3. PubMed ID: 17516714
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.